Related Experiment Video

Updated: Nov 4, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K

A Study of Regulatory Challenges of Pediatric Oncology Phase I/II Trial Submissions and Guidance on Protocol

Lydia Beck1,2,3, Ruth Witt1,2,4,5, Martina Nesper-Brock1,2,4,5

  • 1Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

Clinical Pharmacology and Therapeutics
|May 29, 2021
PubMed

Insights

Identifying deficiencies in pediatric oncology early phase clinical trial protocols in Germany is crucial. Addressing common issues like toxicity and manufacturing can streamline trial development and prevent delays.

Area of Science:

  • Pediatric Oncology
  • Clinical Trial Management
  • Regulatory Affairs

Background:

  • Early phase clinical trials are vital for advancing pediatric cancer treatments.
  • Protocol deficiencies can significantly hinder trial initiation and completion.
  • Understanding regulatory feedback is key to improving trial design.

Purpose of the Study:

  • To identify prevalent deficiencies in pediatric oncology early phase clinical trial protocols submitted in Germany.
  • To offer guidance for more efficient and effective trial protocol development.

Main Methods:

  • Systematic review of response letters from German competent authorities (CAs) and Ethics Committees (ECs) for phase I/II trials (2014-2019).
  • Analysis of deficiencies from 17 trials across 6 sites, categorized by frequency, significance, and feasibility.
  • Validation using a blinded dataset of aggregated data from 33 studies.

Main Results:

  • 250 deficiencies identified, primarily in 'Toxicity and safety' (27.6%) and 'Manufacturing and Import' (18%).
  • Most deficiencies were minor and easily addressable, but a significant portion were major and complex.
  • Ethics Committee deficiencies often resolved by modifying patient-facing documents.

Conclusions:

  • A distinct pattern of key deficiencies in pediatric oncology trial protocols has been identified.
  • Proactive protocol adjustments and increased regulatory awareness can prevent lengthy revisions or rejections.
  • A guideline for key regulatory aspects is provided to aid future protocol development.

More Related Videos

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K
Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

18.4K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.0K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.4K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
58
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
49
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.9K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
71